Promoter hypermethylation occurs in various tumors and leads to silencing of tumor-relevant genes. Thus, promoter methylation analysis (MA) has been established as an important tool in cancer research and diagnostics. Here we present MethyQESD (methylation-quantification of endonuclease-resistant DNA) as a fast, easy, precise and reliable method for quantitative MA without the need of bisulfite-treatment or fluorescent probes. Though MethyQESD principally works with any gene promoter we established MethyQESD for the mismatch repair gene MLH1 and tested its utility to differentiate between sporadic microsatellite unstable (MSI-H) colorectal cancer and hereditary nonpolyposis colorectal cancer (HNPCC) by quantitative MLH1 MA. We investigated formalin-fixed and paraffin-embedded tissue samples from a previously published, well-characterized tumor collective comprising 25 HNPCC, 14 sporadic MSI-H CRC and 16 sporadic microsatellite stable (MSS) CRC. We found a high accuracy of MethyQESD by spiking experiments with dilution series of methylated (SW48 cancer cell line) and unmethylated (blood) DNA (Pearson's r ¼ 0.9997 (proximal MLH1 promoter region), r ¼ 0.9976 (distal MLH1 promoter region)). MethyQESD and conventional quantitative MA using of 96 formalinfixed and paraffin-embedded CRC showed a high degree of concordance of both methods (Pearson's r ¼ 0.885). HNPCC tumors showed either null MLH1 methylation or a significantly lower degree of MLH1 methylation than sporadic MSI-H CRC (Po0.001). MLH1 methylation was negative in all MSS tumors. Receiver operating characteristic (ROC) curve analyses defined a cutoff value of 16.5% MLH1 methylation for specific and sensitive identification of sporadic MSI-H CRC (area under ROC curve: 1.000; asymptotic significance: Po0.001). Thus, quantitative MLH1 MA by MethyQESD provides a simple, fast and valuable tool to identify HNPCC candidates. Furthermore, MethyQESD works reliably with formalin-fixed paraffin-embedded tissue and simplifies DNA MA both for research and diagnostic purposes.
Aberrant CpG methylation patterns have been reported to occur frequently in cancer, 1, 2 where hypermethylation of regulatory CpG islands can lead to the inactivation of a number of tumor-relevant genes. 3, 4 Methylation analysis of defined marker genes is therefore a promising molecular tool with a broad range of application in diagnostics and prediction of response of chemotherapies, [5] [6] [7] but none of the current quantitative techniques of DNA methylation analysis (MA) are suited for routine-diagnostic purposes because of their laborious, complicated and time-consuming procedure.
Promoter hypermethylation of the mismatch repair gene MLH1 leads to a high level of microsatellite instability (MSI-H) 8, 9 and can be found in approximately 15% of sporadic CRC. [10] [11] [12] [13] [14] [15] On the other hand, MSI-H is a hallmark of hereditary nonpolyposis colorectal cancers (HNPCCs) [10] [11] [12] 14, 15 and caused by germline mutations rather than by promoter hypermethylation. 16, 17 For diagnostic purposes, objective quantitative methods with proven cutoff methylation values are required which are validated in well-defined patient collectives.
Recently, we established a quantitative MA technique for HNPCC diagnostics 7 and showed that MLH1 methylation quantification can help to identify HNPCC patients by detection of null or weak MLH1 methylation and to distinguish them from sporadic MSI-H CRC showing virtually constantly high MLH1 methylation levels. Thus, quantitative examination of MLH1 promoter hypermethylation can detect HNPCC candidates who should undergo a MLH1 germline mutation search through DNA sequencing and MLPA analysis. 8, 9, [18] [19] [20] Here we present methylation-quantification of endonucleaseresistant DNA (MethyQESD) as a new, robust, fast and easy quantitative MA technique which works reliably with formalin-fixed and paraffin-embedded tissue and is best suited as a molecular tool both in routine diagnostic practice and in cancer research.
MATERIALS AND METHODS Surgical Specimens and Cell Lines
In a multicentric study 96 formalin-fixed paraffin-embedded tumor samples were obtained from the pathology departments of the University of Regensburg (n ¼ 55), the LudwigMaximilians-University of Munich (n ¼ 29), and the Technical University of Munich (n ¼ 12) and analyzed for MLH1 promoter methylation, BRAF V600E mutation analysis and immunohistochemistry (IHC) of MLH1, MSH2 and MSH6 mismatch repair proteins. A reference group of 55 CRC patients were studied according to microsatellite status, BRAF V600E mutation, MLH1 germline mutation and Amsterdam-1 criteria: (1) HNPCC patients (n ¼ 25) were defined by (i) positive Amsterdam-1 criteria and/or pathogenic MLH1 germline mutations, (ii) microsatellite instability (MSI-H) and (iii) negative MLH1 IHC (median age: 37.0 years); (2) sporadic MSI-H CRC patients (n ¼ 14) were defined by (i) no evidence of fulfilled Amsterdam criteria or MLH1 germline mutations, (ii) BRAF V600E mutation, (iii) age Z75 years and (iv) negative MLH1 IHC (median age: 80.5 years); (3) sporadic microsatellite stable (MSS) CRC patients (n ¼ 16, median age: 76.5) showing MSS and intact expression of the mismatch repair proteins were used as control group.
The human colon cancer cell line SW48 (MLH1 methylation positive) was obtained from ATCC. The cell line was maintained in DMEM with 10% fetal bovine serum at 371C and 5% CO 2 .
DNA Isolation DNA was isolated from blood, archival FFPE tissues and cell lines using the PUREGENEt DNA Purification Kit (Gentra, Minneapolis, MN, USA) according to the supplier's recommendation. DNA was quantified photometrically.
Microsatellite Analysis
Microsatellite analysis was performed as previously described. 21 Briefly, 50-100 ng genomic DNA was used for multiplex microsatellite PCR amplification of the recommended Bethesda standard panel using the HNPCC Microsatellite Instability Test kit (Roche, Mannheim, Germany) according to the manufacturer's instruction. MSI-H was defined by a MSI frequency of 430% 22, 23 according to the Bethesda guidelines. Amplified PCR product (1 ml) was applied to the ABI PRISMt 310 Genetic Analyzer using POP6 polymer. Automatic fragment analysis was performed by GeneScant 3.1.2 software (Applied Biosystems, Darmstadt, Germany).
BRAF Mutation Analysis
Mutation analyses of BRAF codon 600 were performed by sequencing exon 15 using an ABI PRISM 3100 Genetic Analyser. Following primers were used for BRAF V600E mutation: BRAF-600 up: 5 0 -TGTAAAACGACGGCCAGTTC ATAATGCTTGCTCTGATAGGA-3 0 und BRAF-600 down:
Amplifications were carried out according to 7, 24 using 0.02 U/ml Taq DNA polymerase (Fermentas, St. Leon-Rot, Germany) and a PCR profile consisting of a 3-min initial denaturation at 941C followed by 35 cycles of 60 s at 94, 60 and 721C, respectively. Final extension was performed by a 8-min incubation at 721C.
Principle of MethyQESD
The MA is based on a combination of methylation-sensitive digestion and real-time PCR. The proportion of methylated DNA, which resists digestion by the methylation-sensitive endonuclease Hin6I is determined by real-time PCR and calibrated using a reference DNA that remains uncut.
Two restiction digestion batches are prepared for each sample, both of them containing equal amounts of DNA: (1) a methylation-quantification digestion (MQD) containing the methylation-sensitive restriction endonuclease Hin6I that cuts only unmethylated CGCG recognition sites, present within the amplicon. (2) A methylation independent calibrator digestion (CalD) with the endonucleases XbaI and DraI whose recognition sites must not be present within the amplicon. The XbaI/DraI as well as the Hin6I digests generates fragmented genomic DNA with increased PCR-accessibility and a higher PCR amplification efficiency. The XbaI/DraI leads to an equal PCR amplification efficiency but does not prevent amplification of the calibrator DNA. The proportion of methylated DNA is determined by subsequent real-time PCR using the MQD and the CalD as templates. In order to investigate methylation of archival paraffinized tissue samples, the size of the amplicon should range between 80 and 150 bp. The difference of the C t -values give the proportion of methylated DNA according to the formula: methylation ð%Þ ¼ E ðC t CalDÀC t MQDÞ Â100 (E: PCR efficiency). The principle of MethyQESD is illustrated in Figure 1 .
Methylation-Specific Digestion
Two DNA samples each containing 5 ml DNA (1-300 ng/ml) were digested overnight at 371C in a total volume of 20 ml 1xTangot-Buffer (Fermentas) with 30 U Hin6I and XbaI/ DraI (Fermentas; each 15 U), respectively. Subsequently, the endonucleases were inactivated by incubation at 701C for 20 min and the samples were stored at 41C.
Methylation-Specific Quantitative Real-Time PCR
The promoter methylation status was determined by relative quantitative real-time PCR using the LightCycler (Roche). Both, the methylation quantification batch and the calibrator DNA were used for PCR in duplicates.
Digested DNA of the MLH1 methylation-positive CRC cell line SW48 served as control for positive methylation, digested DNA of nonmethylated blood DNA was used as a control for 0% methylation.
Real-time PCR was carried out using the QuantiTect SYBR Green I Kit (Qiagen, Hilden, Germany) with 2 ml digested DNA in a total volume of 20 ml, containing 0.5 mM of each primer and 10 ml 1 Â QuantiTectt SYBR Green I Kit. An initial denaturation for 15 min at 951C was followed by 45 cycles of 951C for 10 s, 601C for 17 s and 721C for 10 s. Melting point analyses were performed by heating the PCR products from 50 to 951C with an increase of 0.21C/s while fluorescence was monitored continuously. Primer sequences were (5 0 -3 0 ): MLH1_prox_MS_up CGGCATCTCTGCTC CTATTG; MLH1_prox_MS_down TGCCCGCTACCTAG AAGGAT; MLH1_dist_MS_up 5 0 -AAGTCGCCCTGAC;GCA GAC; MLH1_dist_MS_down ACTACGAGGCTGAGCACGAA.
The proportion of methylated template was calculated from the differences of the Ct-values from the CalD and MQD ( ¼ DC t ) according to the formula: methylation ð%Þ ¼ E DC t Â100 (E: PCR efficiency).
RESULTS

Restriction Endonuclease Efficiency and Specificity
In order to test the minimum time needed for quantitative digestion of unmethylated DNA we treated 1.3 mg DNA from blood and 1.0 mg DNA from paraffinized normal tissue with Hin6I for different times. After 1 h 99.90% of the blood DNA was completely digested. The restriction efficiency of Hin6I was lower at the DNA from paraffinized tissue, thus complete restriction (0% undigested DNA) was achieved after an incubation time of 16 h ( Figure 2 ). Hin6I has no intrinsic activity on methylated DNA as no degradation of methylated DNA was detectable after incubation with Hin6I for 30 h. We To prove the reliability of the method using formalin-fixed and paraffin-embedded (FFPE) tissue samples we compared the methylation values of the proximal MLH1 promoter region using MethyQESD and quantitative MA using conventional bisulfite-modified DNA [5] [6] [7] of 96 formalin-fixed and paraffin-embedded CRC (Table 1) . We found a high concordance of both methods (Pearson's r ¼ 0.885).
Technical Sensitivity of the MLH1 MethyQESD
The sensitivity was checked by real-time PCR of Hin6I digested dilutions of defined concentrations of DNA from the hypermethylated cell line SW48. The MLH1 MethyQESD was able to detect 3.2 pg of methylated DNA (Figure 4) . The PCR efficiency of the MLH1 MethyQESD PCR was 2.00. For detection of 0% methylation the difference of the C t values must be at least 7.97 (2 À7.97 ¼ 0.004). Thus, the MQD-and CalD real-time PCR reactions must theoretically contain at least 800 pg DNA each to detect 0% methylation.
In addition, DNA was isolated from 10 Quantitative DNA methylation analysis M Bettstetter et al Thus, in most of the HNPCC patients (92%, 23/25) no methylation (ie 0-2% methylation) was detected. However, 8% (2/25) of HNPCC tumors showed low-level methylation (10 and 13%).
The MethyQESD of proximal MLH1 methylation could discriminate between the three tumor groups. A quantile box plot of the median methylation values demonstrates that methylation is significantly different in each tumor group (P Kruskal-Wallis o0.001; Figure 5 ). Sporadic MSI-H CRC showed strong MLH1 promoter methylation (Z21%), whereas HNPCC tumors do not show methylation at all or only low values (up to 13% at most). MSS sporadic tumors which were used as controls are consistently MLH1 methylation negative.
DISCUSSION
The aim of this study was to establish an easy, fast and robust quantitative MA as a molecular tool in research and diagnostics. Generally, several difficulties can complicate methylation analyses. Stromal and inflammatory lymphocytes within tumor tissues can have other methylation patterns than the tumor and may cause false results if nonquantitative MA techniques like simple methylation-specific PCR (MSP) are applied. Moreover, nonquantitative methylation detection techniques principally cannot distinguish between low grade, partial or monoallelic and biallelic methylation.
Beside MSP, other quantitative methylation analyses 25, 26 usually require a time consuming bisulfite modification step which generates unstable modified DNA impairing the speed and reproducibility of analyses. In addition the design of primers or fluorescent probes for the degenerated sequence of bisulfitemodified DNA can be difficult or even impossible for certain promoter regions. Methylation detection by pyrosequencing is a powerful technique, but it includes also a bisulfite modification step and requires a costly technical equipment. These drawbacks could be overcome by the MethyQESD technique which is highly reproducible, easy and sensitive as it uses stable genomic DNA and quantification based on SYBR Green real-time PCR. The high sensitivity of SYBR Green real-time PCR ensures quantification even of very small amounts of DNA, eg DNA from fine-needle biopsies. There is a significant correlation of MethyQESD and PCR using bisulfite modified DNA (Pearson's r ¼ 0.885; Po0.01; SPSS 15.0).
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We show here that only few nanograms of DNA from as little as 100 cells are sufficient for a MA. However, for routine analysis of formalin-fixed paraffin-embedded tumor tissue we recommend to use 50-100 ng for DNA restriction and to take a 10th aliquot (ie 5-10 ng) of digested DNA for quantitative PCR. As higher C t -values are accompanied with an increased standard deviation, we recommend the use of DNA triplicates in the real-time PCR reactions containing less than 2 ng DNA. The small size of the amplicons (80-150 bp) ensures reproducible results from fragmented DNA extracted from formalin-fixed and paraffin-embedded tissue samples. This analytical robustness makes MethyQESD best suited for retrospective studies of archival material. A main advantage of MethyQESD is that no bisulfite modification step is required. Furthermore, the parallel use of a quantification and a calibrator batch of each DNA sample provides a self-calibrating real-time PCR with equal PCR efficiencies. This avoids the need of standard curves as well as the adjustment of DNA concentration. Furthermore, the digested DNA samples can be used for further MethyQESD MA of other genes than MLH1.
As PCR efficiency is enhanced by fragmentation of genomic DNA by endonucleases cutting outside the amplicon (data not shown) undigested DNA should not be used for creating a standard curve to avoid an overestimation of methylation. This issue is unfortunately not considered in another quantitative methylation detection methods. 27 The accuracy of our technique was proven in two different ways. First, we performed spiking experiments of methylated and unmethylated template DNA from a colorectal cancer cell line and blood, respectively (Figure 3 ), and found a high accuracy (Pearson's r ¼ 0.9997 (proximal MLH1 promoter region), r ¼ 0.9976 (distal MLH1 promoter region)). Second, in order to evaluate MethyQESD with routine formalin-fixed and paraffin-embedded tissue samples, we compared the methylation values of the proximal MLH1 promoter region generated with MethyQESD and another quantitative MA using conventional bisulfite-modified DNA 7 of 96 formalinfixed and paraffin-embedded CRC (Table 1) . Both methods showed again a high concordance (Pearson's r ¼ 0.885).
False positive signals from undigested unmethylated DNA can be excluded, as amounts of 1.5 mg DNA from blood are completely digested by Hin6I within 2 h. As Hin6I has no intrinsic activity on methylated restriction sites we digested the DNA overnight, although MethyQESD produces reliable results already within less than 5 h (3 h digestion, 1 h realtime PCR, approximately 20 min hands-on time).
We have established MethyQESD for MLH1 MA as a molecular tool in HNPCC diagnostics as it has been shown that a strong MLH1 methylation occurs in sporadic MSI CRC whereas no or only low levels of MLH1 methylation are present in HNPCC patients. 7 The quantification of MLH1 methylation by MethyQESD allows the distinction between low level methylation due to, eg partial or monoallelic methylation or epigenetic germline defects in HNPCC 28 and biallelic methylation. Thus, MethyQESD significantly improves the accuracy of HNPCC diagnostics as also HNPCC cases with low level of MLH1 methylation can be detected which were otherwise falsely assigned to sporadic MSI CRC.
The lowest value within the group of sporadic MSI-H tumors was 21% ( Figure 5 ) and the highest value in HNPCC The non-parametric Kruskal-Wallis test was used to examine differences between the three independent tumor groups (HNPCC, sporadic MSI-H tumors, sporadic MSS tumors). The Mann-Whitney -U-test was used in case of two tumor groups. P ¼ P-value. Statistical analysis was performed using the SPSS13 software.
Quantitative DNA methylation analysis M Bettstetter et al tumors was 13%. A cutoff value of 16.5% was calculated by a ROC curve analysis. False positive methylation results could be excluded as no positive methylation was detected at any MLH1 expressing MSS CRC. Interestingly, two HNPCC patients (62 and 63 years old, respectively) with pathogenic MLH1 germline mutations and loss of MLH1 expression showed weak DNA MLH1 methylation (10 and 13%, respectively). We assume that these cases carry monoallelic MLH1 promoter methylation, ie one allele is silenced by methylation, whereas the other allele carries the MLH1 germline mutation. Unfortunately, we were not able to discriminate between maternal and paternal alleles to verify monoallelic methylation by cloning and sequence analysis as there was no sequence polymorphism within the promoter regions.
Although MLH1 MA by MethyQESD is not a stand-alone test in HNPCC diagnostics, MethyQESD is a valuable tool to identify HNPCC candidates for further analysis like mutation analysis of MMR genes. In addition to MLH1 methylation, a BRAF V600E mutation has been reported to occur specifically in about 70% of sporadic MSI-H CRC. 29, 30 Although the detection of a BRAF V600E mutation may exclude HNPCC, wildtype BRAF V600 can occur in both sporadic CRC and HNPCC making a BRAF V600 wild-type result meaningless. However, for best diagnostic results we recommend to perform both MLH1 MethyQESD and BRAF V600E analysis in all CRC with MSI-H and lack of MLH1 protein expression. Patients without significant MLH1 methylation and with wild-type BRAF V600 represent HNPCC candidates who should further clarified by genetic counseling and who might benefit from a tight surveillance program.
In summary, MethyQESD is a robust, fast, reliable and easy-to-handle method for quantitative MA. MethyQESD avoids a bisulfite modification step and can readily be established also for MA of other genes as we have performed it already for MGMT, P16, GSTP1, RASSF1, SFRP1, PITX2, CA4, NEUROG1, CDH3 and APC. As MethyQESD works reliably with formalin-fixed and paraffin-embedded tissue MethyQESD is ideally suited for quantitative methylation analyses both in diagnostic purposes and for research studies using archival tissues.
